Top

Published in:

Open Access 01-12-2016 | Review

Hyaluronidase: from clinical applications to molecular and cellular mechanisms

Authors: Bettina Alexandra Buhren, Holger Schrumpf, Norman-Philipp Hoff, Edwin Bölke, Said Hilton, Peter Arne Gerber

Published in: European Journal of Medical Research | Issue 1/2016

Abstract

Over the past 60 years, hyaluronidase has been successfully utilized in ophthalmic surgery and is now being implemented in dermatosurgery as well as in other surgical disciplines. The enzyme is considered a “spreading factor” as it decomplexes hyaluronic acid (also called hyaluronan, HA), an essential component of the extracellular matrix (ECM). When applied as an adjuvant, hyaluronidase enhances the diffusion capacity and bioavailability of injected drugs. Therefore, the enzyme has been used as a local adjuvant to increase the diffusion capacity of local anesthetics, increasing the analgesic efficacy, and the anesthetized area particularly in the first minutes following injection, resulting in diminished intra- and postoperative pain. In aesthetic medicine, the off-label use of hyaluronidase is considered the gold standard for the management of HA-filler-associated complications. Here, we review the clinical use, underlying biological mechanisms, and future directions for the application of hyaluronidase in surgical and aesthetic medicine.

Bissell MJ, Hall HG, Parry G. How does the extracellular matrix direct gene expression? J Theor Biol. 1982;99(1):31–68.CrossRefPubMed

Juhlin L. Hyaluronan in skin. J Intern Med. 1997;242(1):61–6.CrossRefPubMed

Laurent TC, Fraser JR. Hyaluronan. FASEB J. 1992;6(7):2397–404.PubMed

Tammi R, Ripellino JA, Margolis RU, Tammi M. Localization of epidermal hyaluronic acid using the hyaluronate binding region of cartilage proteoglycan as a specific probe. J Invest Dermatol. 1988;90(3):412–4.CrossRefPubMed

Scott JE. Supramolecular organization of extracellular matrix glycosaminoglycans, in vitro and in the tissues. FASEB J. 1992;6(9):2639–45.PubMed

Csoka AB, Frost GI, Stern R. The six hyaluronidase-like genes in the human and mouse genomes. Matrix Biol. 2001;20(8):499–508.CrossRefPubMed

Stern R, Jedrzejas MJ. Hyaluronidases: their genomics, structures, and mechanisms of action. Chem Rev. 2006;106(3):818–39. doi:10.1021/cr050247k.PubMedCentralCrossRefPubMed

Lin Y, Mahan K, Lathrop WF, Myles DG, Primakoff P. A hyaluronidase activity of the sperm plasma membrane protein PH-20 enables sperm to penetrate the cumulus cell layer surrounding the egg. J Cell Biol. 1994;125(5):1157–63.CrossRefPubMed

West DC, Hampson IN, Arnold F, Kumar S. Angiogenesis induced by degradation products of hyaluronic acid. Science. 1985;228(4705):1324–6.CrossRefPubMed

10.

Kaya G, Tran C, Sorg O, Hotz R, Grand D, Carraux P, et al. Hyaluronate fragments reverse skin atrophy by a CD44-dependent mechanism. PLoS Med. 2006;3(12):e493. doi:10.1371/journal.pmed.0030493.PubMedCentralCrossRefPubMed

11.

Delmage JM, Powars DR, Jaynes PK, Allerton SE. The selective suppression of immunogenicity by hyaluronic acid. Ann Clin Lab Sci. 1986;16(4):303–10.PubMed

12.

Feinberg RN, Beebe DC. Hyaluronate in vasculogenesis. Science. 1983;220(4602):1177–9.CrossRefPubMed

13.

McBride WH, Bard JB. Hyaluronidase-sensitive halos around adherent cells. Their role in blocking lymphocyte-mediated cytolysis. J Exp Med. 1979;149(2):507–15.CrossRefPubMed

14.

Girish KS, Kemparaju K. The magic glue hyaluronan and its eraser hyaluronidase: a biological overview. Life Sci. 2007;80(21):1921–43. doi:10.1016/j.lfs.2007.02.037.CrossRefPubMed

15.

Tian X, Azpurua J, Hine C, Vaidya A, Myakishev-Rempel M, Ablaeva J, et al. High-molecular-mass hyaluronan mediates the cancer resistance of the naked mole rat. Nature. 2013;499(7458):346–9. doi:10.1038/nature12234.PubMedCentralCrossRefPubMed

16.

West DC, Kumar S. The effect of hyaluronate and its oligosaccharides on endothelial cell proliferation and monolayer integrity. Exp Cell Res. 1989;183(1):179–96.CrossRefPubMed

17.

Jiang D, Liang J, Fan J, Yu S, Chen S, Luo Y, et al. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med. 2005;11(11):1173–9. doi:10.1038/nm1315.CrossRefPubMed

18.

Jiang D, Liang J, Noble PW. Hyaluronan as an immune regulator in human diseases. Physiol Rev. 2011;91(1):221–64. doi:10.1152/physrev.00052.2009.PubMedCentralCrossRefPubMed

19.

McKee CM, Penno MB, Cowman M, Burdick MD, Strieter RM, Bao C, et al. Hyaluronan (HA) fragments induce chemokine gene expression in alveolar macrophages. The role of HA size and CD44. J Clin Invest. 1996;98(10):2403–13. doi:10.1172/JCI119054.PubMedCentralCrossRefPubMed

20.

Csoka TB, Frost GI, Stern R. Hyaluronidases in tissue invasion. Invasion Metastasis. 1997;17(6):297–311.PubMed

21.

Makris G, Wright JD, Ingham E, Holland KT. The hyaluronate lyase of Staphylococcus aureus—a virulence factor? Microbiology. 2004;150(Pt 6):2005–13. doi:10.1099/mic.0.26942-0.CrossRefPubMed

22.

Wohlrab J, Finke R, Franke WG, Wohlrab A. Clinical trial for safety evaluation of hyaluronidase as diffusion enhancing adjuvant for infiltration analgesia of skin with lidocaine. Dermatol Surg. 2012;38(1):91–6. doi:10.1111/j.1524-4725.2011.02146.x.CrossRefPubMed

23.

Moharib MM, Mitra S. Alkalinized lidocaine and bupivacaine with hyaluronidase for sub-tenon’s ophthalmic block. Reg Anesth Pain Med. 2000;25(5):514–7. doi:10.1053/rapm.2000.5664.PubMed

24.

Narayanan R, Kuppermann BD. Hyaluronidase for pharmacologic vitreolysis. Dev Ophthalmol. 2009;44:20–5. doi:10.1159/000223941.CrossRefPubMed

25.

Nicoll JM, Treuren B, Acharya PA, Ahlen K, James M. Retrobulbar anesthesia: the role of hyaluronidase. Anesth Analg. 1986;65(12):1324–8.CrossRefPubMed

26.

Sarvela PJ, Paloheimo MP, Nikki PH. Comparison of pH-adjusted bupivacaine 0.75 % and a mixture of bupivacaine 0.75% and lidocaine 2 %, both with hyaluronidase, in day-case cataract surgery under regional anesthesia. Anesth Analg. 1994;79(1):35–9.CrossRefPubMed

27.

Fratila A. Einsatz von hyaluronidase bei blepharoplastiken. Aesthet Dermatol. 2013;2:2–6.

28.

Rzany B, Becker-Wegerich P, Bachmann F, Erdmann R, Wollina U. Hyaluronidase in the correction of hyaluronic acid-based fillers: a review and a recommendation for use. J Cosmet Dermatol. 2009;8(4):317–23. doi:10.1111/j.1473-2165.2009.00462.x.CrossRefPubMed

29.

Wohlrab J, Wohlrab D, Wohlrab L, Wohlrab C, Wohlrab A. Use of hyaluronidase for pharmacokinetic increase in bioavailability of intracutaneously applied substances. Skin Pharmacol Physiol. 2014;27(5):276–82. doi:10.1159/000360545.CrossRefPubMed

30.

Thorpe JN. Procaine with hyaluronidase as local anesthetic. Lancet. 1951;1(6648):210–1.CrossRefPubMed

31.

Clark LE, Mellette JR Jr. The use of hyaluronidase as an adjunct to surgical procedures. J Dermatol Surg Oncol. 1994;20(12):842–4.CrossRefPubMed

32.

Wohlrab J, Finke R, Franke WG, Wohlrab A. Efficacy study of hyaluronidase as a diffusion promoter for lidocaine in infiltration analgesia of skin. Plast Reconstr Surg. 2012;129(4):771e–2e. doi:10.1097/PRS.0b013e318245ea27.CrossRefPubMed

33.

Nevarre DR, Tzarnas CD. The effects of hyaluronidase on the efficacy and on the pain of administration of 1 % lidocaine. Plast Reconstr Surg. 1998;101(2):365–9.CrossRefPubMed

34.

Meyer LJ, Stern R. Age-dependent changes of hyaluronan in human skin. J Invest Dermatol. 1994;102(3):385–9.CrossRefPubMed

35.

Stern R, Maibach HI. Hyaluronan in skin: aspects of aging and its pharmacologic modulation. Clin Dermatol. 2008;26(2):106–22. doi:10.1016/j.clindermatol.2007.09.013.CrossRefPubMed

36.

Brody HJ. Use of hyaluronidase in the treatment of granulomatous hyaluronic acid reactions or unwanted hyaluronic acid misplacement. Dermatol Surg. 2005;31(8 Pt 1):893–7.CrossRefPubMed

37.

Hirsch RJ, Cohen JL, Carruthers JD. Successful management of an unusual presentation of impending necrosis following a hyaluronic acid injection embolus and a proposed algorithm for management with hyaluronidase. Dermatol Surg. 2007;33(3):357–60. doi:10.1111/j.1524-4725.2007.33073.x.PubMed

38.

Hirsch RJ, Brody HJ, Carruthers JD. Hyaluronidase in the office: a necessity for every dermasurgeon that injects hyaluronic acid. J Cosmet Laser Ther. 2007;9(3):182–5. doi:10.1080/14764170701291674.CrossRefPubMed

39.

Jahn K, Homey B, Gerber PA. Management of complications after aesthetic hyaluronic acid injections. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete. 2014;65(10):851–3. doi:10.1007/s00105-014-3511-y.CrossRefPubMed

40.

Hilton S, Schrumpf H, Buhren BA, Bolke E, Gerber PA. Hyaluronidase injection for the treatment of eyelid edema: a retrospective analysis of 20 patients. Eur J Med Res. 2014;19:30. doi:10.1186/2047-783X-19-30.PubMedCentralCrossRefPubMed

41.

Kim DW, Yoon ES, Ji YH, Park SH, Lee BI, Dhong ES. Vascular complications of hyaluronic acid fillers and the role of hyaluronidase in management. J Plast Reconstr Aesthet Surg. 2011;64(12):1590–5. doi:10.1016/j.bjps.2011.07.013.CrossRefPubMed

42.

Allen CH, Etzwiler LS, Miller MK, Maher G, Mace S, Hostetler MA, et al. Recombinant human hyaluronidase-enabled subcutaneous pediatric rehydration. Pediatrics. 2009;124(5):e858–67. doi:10.1542/peds.2008-3588.CrossRefPubMed

43.

Shpilberg O, Jackisch C. Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase. Br J Cancer. 2013;109(6):1556–61. doi:10.1038/bjc.2013.371.PubMedCentralCrossRefPubMed

Title: Hyaluronidase: from clinical applications to molecular and cellular mechanisms
Authors: Bettina Alexandra Buhren
Holger Schrumpf
Norman-Philipp Hoff
Edwin Bölke
Said Hilton
Peter Arne Gerber
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: European Journal of Medical Research / Issue 1/2016
Electronic ISSN: 2047-783X
DOI: https://doi.org/10.1186/s40001-016-0201-5

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Hyaluronidase: from clinical applications to molecular and cellular mechanisms

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2016

Serum prolactin as a biomarker for the study of intracerebral dopamine effect in adult patients with phenylketonuria: a cross-sectional monocentric study

Hyperoxia increases arterial oxygen pressure during exercise in type 2 diabetes patients: a feasibility study

sMICA as novel and early predictors for acute myocardial infarction

One-lung flooding reduces the ipsilateral diaphragm motion during mechanical ventilation

Pseudoaneurysm of the anterior tibial artery after interlocking tibial nailing: an unexpected complication

Evaluation and clinical significance of cyclin-dependent kinase5 expression in cervical lesions: a clinical research study in Guangxi, China